HEATHER WINQUIST: Open Payments
NPI 1972018398 · NORMAL, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$791 in 42 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $111 · 2025 $791
Food & beverage: $781Education: $9
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $248 |
| Janssen Biotech, Inc. | 13 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $132 |
| Aimmune Therapeutics, Inc. | 3 | $65 |
| Madrigal Pharmaceuticals | 2 | $44 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
| Lilly USA, LLC | 1 | $28 |
| Novo Nordisk Inc | 1 | $19 |
| Ardelyx, Inc. | 1 | $16 |
| Janssen Pharmaceuticals, Inc | 1 | $9 |
Products named: TREMFYA, RINVOQ, SKYRIZI, ENTYVIO, ZENPEP, REZDIFFRA, XIFAXAN, EOHILIA.
Industry payments across IL — which companies pay providers there.
